Cantor Fitzgerald Remains a Hold on Rigel (RIGL) - Markets Insider

Dec 10, 2024 · In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Hold rating on Rigel (RIGL – Research Report), with a price target of $25.00. The company’s …

$25.00
OFF

Cantor Fitzgerald Remains A Hold On Rigel (RIGL) - Markets Insider

1 week from now

Dec 10, 2024 · In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Hold rating on Rigel (RIGL – Research Report), with a price target of $25.00. The company’s …

businessinsider.com

$15.00
OFF

Cantor Fitzgerald Issues Positive Forecast For Rigel Pharmaceuticals ...

1 week from now

Dec 11, 2024 · Rigel Pharmaceuticals (NASDAQ:RIGL – Free Report) had its target price lifted by Cantor Fitzgerald from $15.00 to $25.00 in a research report released on Tuesday …

etfdailynews.com

$25
OFF

Rigel Pharmaceuticals Price Target Raised To $25 From $15 At …

1 week from now

Dec 10, 2024 · Cantor Fitzgerald raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $25 from $15 and keeps a Neutral rating on the shares. ... Cantor Fitzgerald Remains a Hold …

businessinsider.com

$25
OFF

Rigel’s Robust Financial Performance And Strategic Partnerships …

1 week from now

Nov 8, 2024 · Cantor Fitzgerald Remains a Hold on Rigel (RIGL) TipRanks 31d. Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald.

businessinsider.com

$25
OFF

RIGL Stock Price | Rigel Pharmaceuticals Inc. Stock Quote (U.S.: …

1 week from now

4 days ago · Cantor Fitzgerald Remains a Hold on Rigel (RIGL) Dec. 10, 2024 at 9:45 a.m. ET on TipRanks.com Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald

marketwatch.com

$15
OFF

Cantor Fitzgerald Maintains Neutral On Rigel Pharmaceuticals, …

1 week from now

Dec 10, 2024 · Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $15 to $25.

sahmcapital.com

$15.00
OFF

Cantor Fitzgerald Boosts Rigel Pharmaceuticals (NASDAQ:RIGL) …

1 week from now

Dec 13, 2024 · Rigel Pharmaceuticals (NASDAQ:RIGL – Free Report) had its target price hoisted by Cantor Fitzgerald from $15.00 to $25.00 in a report published on Tuesday,Benzinga …

americanbankingnews.com

$25.00
OFF

Rigel Pharmaceuticals (NASDAQ:RIGL) Stock, Analyst Ratings, Price ...

1 week from now

The latest price target for Rigel Pharmaceuticals (NASDAQ:RIGL) was reported by Cantor Fitzgerald on December 10, 2024. The analyst firm set a price target for $25.00 expecting …

benzinga.com

$25
OFF

RIGL: Rigel Pharmaceuticals - 12 Month EPS - Zacks.com

1 week from now

Dec 27, 2024 · Cantor Fitzgerald Remains a Hold on Rigel (RIGL) 12/10/24-8:46AM EST TipRanks Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald …

zacks.com

$15.00
OFF

Fmr LLC Increases Stock Position In Rigel ... - ETF Daily News

1 week from now

Dec 18, 2024 · Several equities research analysts recently weighed in on RIGL shares. Cantor Fitzgerald lifted their price objective on Rigel Pharmaceuticals from $15.00 to $25.00 and gave …

etfdailynews.com

$25
OFF

Rigel Pharmaceuticals Inc. Q3 Earnings Summary - Markets Insider

1 week from now

Nov 7, 2024 · Cantor Fitzgerald Remains a Hold on Rigel (RIGL) TipRanks 31d. Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald.

businessinsider.com

$25
OFF

Rigel Granted Orphan Status For Myelodysplastic Syndromes …

1 week from now

Jan 7, 2025 · Cantor Fitzgerald Remains a Hold on Rigel (RIGL) TipRanks 29d. Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald.

businessinsider.com

$2.00
OFF

Cantor Fitzgerald Raises Rigel Pharmaceuticals (NASDAQ:RIGL) …

1 week from now

Mar 7, 2024 · Rigel Pharmaceuticals (NASDAQ:RIGL – Free Report) had its price objective increased by Cantor Fitzgerald from $2.00 to $3.00 in a research note published on …

americanbankingnews.com

$57.00
OFF

Strong Commercial Performance And Promising Pipeline Drive …

1 week from now

3 days ago · Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Rigel (RIGL – Research Report). The associated price target remains the same with $57.00. …

businessinsider.com

FAQs about Cantor Fitzgerald Remains a Hold on Rigel (RIGL) - Markets Insider Coupon?

What is Cantor Fitzgerald's price target on Rigel Pharmaceuticals (Rigl)?

Read More on RIGL: Cantor Fitzgerald raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $25 from $15 and keeps a Neutral rating on the shares. Rigel... ...

Should you buy Rigel Pharmaceuticals (Rigl)?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RIGL shares. ...

Should you buy Rigl (Rigl)?

There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares. ...

How did Rigel perform compared to last year?

Based on Rigel’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $55.31 million and a net profit of $12.42 million. In comparison, last year the company earned a revenue of $28.13 million and had a GAAP net loss of $5.69 million ...

How did Rigel perform in the third quarter of 2024?

Rigel’s recent financial results for the third quarter of 2024 surpassed expectations, with an EPS of $0.70 compared to the estimates of ($0.21) and $0.06. Total revenue also exceeded projections, coming in at $55.31 million against estimates of $37.73 million and $41.93 million. ...

Who owns Rigel Pharmaceuticals?

The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA. ...